These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 37490255)

  • 1. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma.
    Vahabi M; Dehni B; Antomás I; Giovannetti E; Peters GJ
    Cancer Metastasis Rev; 2023 Sep; 42(3):725-740. PubMed ID: 37490255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
    Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
    Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
    Giulietti M; Occhipinti G; Principato G; Piva F
    Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
    Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
    Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of miRNAs Targeting the IGF-1R Pathway in Pancreatic Ductal Adenocarcinoma.
    Dobre M; Herlea V; Vlăduţ C; Ciocîrlan M; Balaban VD; Constantinescu G; Diculescu M; Milanesi E
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.
    Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E
    Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression.
    Hawa Z; Haque I; Ghosh A; Banerjee S; Harris L; Banerjee SK
    Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
    Steele CW; Oien KA; McKay CJ; Jamieson NB
    Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potential.
    Fuller RN; Morcos A; Bustillos JG; Molina DC; Wall NR
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189153. PubMed ID: 38986720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
    Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
    Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma.
    Supadmanaba IGP; Mantini G; Randazzo O; Capula M; Muller IB; Cascioferro S; Diana P; Peters GJ; Giovannetti E
    Epigenetics; 2022 Apr; 17(4):381-404. PubMed ID: 34057028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-10b inhibits migration and invasion of pancreatic ductal adenocarcinoma via regulating E2F7.
    Xu C; Qi X
    J Clin Lab Anal; 2020 Oct; 34(10):e23442. PubMed ID: 32592206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
    PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
    Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
    Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Shimura T; Mallik S; Sonohara F; Tsai S; Evans DB; Kim SC; Baba H; Kodera Y; Von Hoff D; Chen X; Goel A
    Ann Surg; 2022 Jan; 275(1):e229-e237. PubMed ID: 32398486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.